CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Jessica Li et al.|Blood|2023Cited by 99
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-upRocío Montes de, Enrique Zudaire, Junchen Gu et al.|Blood|2023Cited by 9